背景:可穿戴技术的目的,连续,并开发了可靠的酒精监测。这些被称为经皮酒精传感器(TASs)。它们可以戴在手腕或脚踝上,传感器压在皮肤上,可以测量从皮肤散发的汗液蒸气,记录经皮酒精浓度(TAC)。以前的研究已经调查了现有TAS品牌的准确性和可接受性,但是很少有研究将它们用于患有酒精使用障碍(AUD)的人。
目的:本可行性随机对照试验旨在探讨可行性,优势,以及在有或没有应急管理(CM)以促进禁欲或低水平饮酒的AUD治疗中使用TAS监测个体饮酒的局限性。
方法:目标样本量为30(每组随机分配15个)。参与者将通过酒精服务的海报广告招募。两组(对照组和CM)将在常规治疗的情况下佩戴TAS(BACtrackSkyn)2周,每隔一个工作日与研究人员会面。在上次会议上,参与者将完成一项关于他们佩戴TAS经验的后装调查。CM集团还将获得低酒精消费或无酒精消费的小额经济奖励,由TAS测量。在TAC峰值低于设定阈值(<115.660g/L)的日子,CM小组参与者将获得5英镑(6.38美元)的优惠券。如果连续几天实现此目标,则有财务奖金。研究人员将在每次研究访问时监测研究的每一天的TAC,并根据设定的强化时间表为参与者分配经济奖励。
结果:第一位参与者于2023年6月注册,最后一位在2023年12月注册。数据分析正在进行中,估计将于2024年6月完成。共招募了32名参与者。
结论:大多数TAS品牌在临床环境中的应用有限,大多数研究包括健康的成年人,而不是AUD患者。TAS有可能提高临床酒精治疗的治疗效果。准确性,可接受性,需要研究TAS在临床环境中对AUD患者的可行性。这是第一项在专门的酒精服务中使用TAS的研究,其中诊断出AUD个体目前正在接受伦敦南部酒精服务的治疗。
背景:ISRCTN注册表ISRCTN46845361;https://www。isrctn.com/ISRCTN46845361.
■DERR1-10.2196/57653。
BACKGROUND: Wearable technology for objective, continuous, and reliable alcohol monitoring has been developed. These are known as
transdermal alcohol sensors (TASs). They can be worn on the wrist or ankle with the sensor pressed against the skin and can measure sweat vapors being emitted from the skin, to record
transdermal alcohol concentration (TAC). Previous studies have investigated the accuracy and acceptability of the available TAS brands, but there has been little research into their use in people with alcohol use disorders (AUD).
OBJECTIVE: This feasibility randomized controlled trial aims to explore the feasibility, strengths, and limitations of using a TAS to monitor alcohol consumption in individuals in treatment for AUD with or without contingency management (CM) to promote abstinence or low-level alcohol consumption.
METHODS: The target sample size is 30 (15 randomized to each group). Participants will be recruited through poster adverts at alcohol services. Both groups (control and CM) will wear the TAS (BACtrack Skyn) for 2 weeks in the context of their usual treatment, meeting with the researcher every other weekday. In the last meeting, the participants will complete a postwear survey on their experience of wearing the TAS. The CM group will also receive small financial incentives for low or no alcohol consumption, as measured by the TAS. On days where the TAC peak is below a set threshold (<115.660 g/L), CM group participants will be rewarded with a £5 (US $6.38) voucher. There are financial bonuses if this target is achieved on consecutive days. The researcher will monitor TAC for each day of the study at each research visit and allocate financial incentives to participants according to a set reinforcement schedule.
RESULTS: The first participant was enrolled in June 2023, and the last in December 2023. Data analysis is underway and is estimated to be completed by June 2024. A total of 32 participants were enrolled.
CONCLUSIONS: Most TAS brands have had limited application in clinical settings, and most studies have included healthy adults rather than people with AUD. TAS has the potential to enhance treatment outcomes in clinical alcohol treatment. The accuracy, acceptability, and feasibility of TAS for people with AUD in clinical settings need to be investigated. This is the first study to use TAS in specialized alcohol services with diagnosed AUD individuals currently receiving treatment from a south London alcohol service.
BACKGROUND: ISRCTN Registry ISRCTN46845361; https://www.isrctn.com/ISRCTN46845361.
UNASSIGNED: DERR1-10.2196/57653.